The Food and Drug Administration (FDA) has announced a proposal to simplify the research process for biosimilar products. The agency is considering changes that would make it easier for biosimilars to be approved as interchangeable with brand-name biologic drugs.
Under the new proposal, the FDA suggests that comparative efficacy studies might not always be required to demonstrate that a biosimilar is similar enough to its reference product. Instead, developers could focus on conducting comparative analytical assessments, which evaluate the differences between the biosimilar and its original counterpart.
According to the FDA, these changes are intended to help streamline development and approval processes for biosimilars. The goal is also to promote greater use of interchangeable biosimilars in healthcare settings.
"Comparative efficacy studies may not be necessary for supporting a demonstration of biosimilarity," said an FDA spokesperson. "We recommend developers consider conducting a comparative analytical assessment to test the differences between the biosimilar and its reference product."
This move by the FDA reflects ongoing efforts within regulatory agencies to increase access to affordable medicines while maintaining standards for safety and effectiveness.
Alerts Sign-up